Insulin/IGF-1 and TNF-α stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways

Insulin/IGF-1 and TNF-α stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways
复制标题

DOI:
10.1172/jci10934
复制
发表时间:
2001-01-01
影响因子:
15.9
通讯作者:
White, MF
White, MF
中科院分区:
医学1区
文献类型:
--
作者:
Rui, LY;Aguirre, V;White, MF

文献摘要

被引文献

相似文献

IRS-1的丝氨酸/苏氨酸磷酸化可能抑制胰岛素信号传导,但相关的磷酸化位点难以在培养细胞中鉴定,也难以在分离的组织中验证。最近,我们发现重组NH 2-末端Jun激酶磷酸化IRS-1的Ser(307),这抑制胰岛素刺激的IRS-1的酪氨酸磷酸化。为了监测不同细胞和组织背景中Ser(307)的磷酸化,我们制备了磷酸化特异性多克隆抗体,命名为α pSer(307)。该抗体显示TNF-α、IGF-1或胰岛素刺激3 T3-L1前脂肪细胞和脂肪细胞中IRS-1在Ser(307)处的磷酸化。注射胰岛素到小鼠或大鼠中也刺激从肌肉免疫沉淀的IRS-1上的Ser(307)的磷酸化;此外,在高胰岛素血症正葡萄糖钳夹过程中,人肌肉中的Ser(307)被磷酸化。3 T3-L1前脂肪细胞和脂肪细胞的实验表明,LY 294002或渥曼青霉素抑制胰岛素刺激的Ser 307磷酸化,而PD 98059抑制TNF-α刺激的磷酸化。因此,不同的激酶途径可能在Ser(307)处会聚,以介导IRS-1信号传导的反馈或异源抑制,从而反调节胰岛素反应。
Serine/threonine phosphorylation of IRS-1 might inhibit insulin signaling, but the relevant phosphorylation sites are difficult to identify in cultured cells and to validate in isolated tissues. Recently, we discovered that recombinant NH2-terminal Jun kinase phosphorylates IRS-1 at Ser(307), which inhibits insulin-stimulated tyrosine phosphorylation of IRS-1. To monitor phosphorylation of Ser(307) in various cell and tissue backgrounds, we prepared a phosphospecific polyclonal antibody designated alpha pSer(307). This antibody revealed that TNF-alpha, IGF-1, or insulin stimulated phosphorylation of IRS-1 at Ser(307) in 3T3-L1 preadipocytes and adipocytes. Insulin injected into mice or rats also stimulated phosphorylation of Ser(307) on IRS-1 immunoprecipitated from muscle; moreover, Ser(307) was phosphorylated in human muscle during the hyperinsulinemic euglycemic clamp. Experiments in 3T3-L1 preadipocytes and adipocytes revealed that insulin-stimulated phosphorylation of Ser(307) was inhibited by LY294002 or wortmannin, whereas TNF-alpha -stimulated phosphorylation was inhibited by PD98059. Thus, distinct kinase pathways might converge at Ser(307) to mediate feedback or heterologous inhibition of IRS-1 signaling to counterregulate the insulin response.